Clinical Trial

FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma

Study acronym: FAD-HCC-001
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC). The study uses a metabolic classification system called the fatty acid degradation (FAD) subtype to guide therapy selection. Patients will be assigned to different treatment groups based on their tumor's FAD subtype, determined through RNA-seq analysis of the tumor tissue obtained from liver biopsy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Trial Details
NCT Number NCT07314372
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
Enrollment 86 participants
Start Date 2026-02-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20